NASDAQ:ATHE Alterity Therapeutics (ATHE) Stock Price, News & Analysis $1.66 -0.05 (-2.65%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.03 (+1.81%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Alterity Therapeutics Stock (NASDAQ:ATHE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alterity Therapeutics alerts:Sign Up Key Stats Today's Range$1.52▼$1.7150-Day Range$1.66▼$4.0552-Week Range$1.52▼$5.89Volume36,187 shsAverage Volume234,568 shsMarket Capitalization$30.01 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Alterity Therapeutics is an Australian clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on conditions associated with abnormal protein accumulation and disrupted iron balance in the brain, including multiple system atrophy (MSA) and Parkinson’s disease. The company’s lead candidate, ATH434, is an investigational small-molecule therapy being studied for MSA. Alterity is evaluating the treatment in clinical trials; it is not an approved medicine. The company’s clinical development has included work in Australia and the United States. Alterity was previously known as Prana Biotechnology and adopted its current name in 2019. Its shares trade on the Nasdaq under the symbol ATHE.AI Generated. May Contain Errors. Read More Alterity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreATHE MarketRank™: 2.95254470426 of 5 starsAlterity Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 333rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingAlterity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAlterity Therapeutics has a consensus price target of $10.00, representing about 504.2% upside from its current price of $1.66.Amount of Analyst CoverageAlterity Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Alterity Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Alterity Therapeutics are expected to remain at ($0.12) per share in the coming year.Price to Book Value per Share RatioAlterity Therapeutics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of Alterity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlterity Therapeutics has a short interest ratio ("days to cover") of 0.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alterity Therapeutics has recently decreased by 36.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlterity Therapeutics does not currently pay a dividend.Dividend GrowthAlterity Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Alterity Therapeutics this week, compared to 2 articles on an average week. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $23,810.00 in company stock, which represents 0.0794% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Alterity Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,810.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.14% of the stock of Alterity Therapeutics is held by institutions.Read more about Alterity Therapeutics' insider trading history. Receive ATHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATHE Stock News HeadlinesAlterity Therapeutics (NASDAQ:ATHE) Stock Falls 4.8% - Here's What HappenedNovember 18 at 3:00 AM | americanbankingnews.comAlterity Therapeutics to Present at the Virtual Bell Potter Healthcare ConferenceNovember 12, 2026 | globenewswire.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 19 at 1:00 AM | Behind the Markets (Ad)Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate UpdateOctober 30, 2026 | globenewswire.comAlterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceOctober 9, 2026 | globenewswire.comAlterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement DisordersOctober 5, 2026 | finance.yahoo.comAlterity's ATH434 Demonstrates Slower MSA Progression In Phase 2October 5, 2026 | rttnews.comAlterity Therapeutics Reports New ATH434 Data In MSAOctober 5, 2026 | rttnews.comSee More Headlines ATHE Stock Analysis - Frequently Asked Questions How have ATHE shares performed this year? Alterity Therapeutics' stock was trading at $3.08 at the beginning of the year. Since then, ATHE shares have decreased by 46.3% and is now trading at $1.6550. How were Alterity Therapeutics' earnings last quarter? Alterity Therapeutics Limited - Sponsored ADR (NASDAQ:ATHE) released its earnings results on Thursday, July, 30th. The company reported ($0.28) EPS for the quarter. The business had revenue of $312.66 thousand for the quarter. When did Alterity Therapeutics' stock split? Shares of Alterity Therapeutics reverse split on the morning of Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Alterity Therapeutics? Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alterity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Palantir Technologies (PLTR), Plug Power (PLUG), Shopify (SHOP), Tesla (TSLA), GE Aerospace (GE), Anavex Life Sciences (AVXL) and Bionano Genomics (BNGO). Company Calendar Last Earnings7/30/2026Today11/19/2026AGM 202611/19/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ATHE's financial health is in the Red zone, according to TradeSmith. ATHE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ATHE CIK1131343 Webalteritytx.com Phone(139) 349-4906Fax61-3-9348-0377Employees11Year Founded1997Price Target and Rating Average Price Target for Alterity Therapeutics$10.00 High Price Target$16.00 Low Price Target$2.00 Potential Upside/Downside+504.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio14.52 Quick Ratio14.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.60 per share Price / Book1.03Miscellaneous Outstanding Shares18,130,000Free Float11,093,000Market Cap$30.01 million OptionableNot Optionable Beta0.36 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ATHE) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.